MX2019006548A - Composicion para el tratamiento de la osteoartritis. - Google Patents

Composicion para el tratamiento de la osteoartritis.

Info

Publication number
MX2019006548A
MX2019006548A MX2019006548A MX2019006548A MX2019006548A MX 2019006548 A MX2019006548 A MX 2019006548A MX 2019006548 A MX2019006548 A MX 2019006548A MX 2019006548 A MX2019006548 A MX 2019006548A MX 2019006548 A MX2019006548 A MX 2019006548A
Authority
MX
Mexico
Prior art keywords
composition
osteoarthritis
treatment
once
articularly
Prior art date
Application number
MX2019006548A
Other languages
English (en)
Inventor
Neggiani Fabio
Trasciatti Silvia
Original Assignee
Abiogen Pharma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abiogen Pharma Spa filed Critical Abiogen Pharma Spa
Publication of MX2019006548A publication Critical patent/MX2019006548A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178Syringes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)

Abstract

La presente invencion se refiere a una composicion para su uso en el tratamiento de la osteoartritis (OA), en donde dicha composicion comprende de 5 a 40 mg de clodronato de sodio, o una cantidad equivalente de acido clodronico, u otras sales farmaceuticamente aceptables de los mismos, y en donde dicha composicion se administra por via intra-articular en una forma de dosificacion unitaria una vez al mes, una vez cada dos semanas o una vez por semana; se describen tambien medicamentos de una sola dosis y kits que los comprenden.
MX2019006548A 2016-12-06 2017-12-06 Composicion para el tratamiento de la osteoartritis. MX2019006548A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102016000123773A IT201600123773A1 (it) 2016-12-06 2016-12-06 Composizione per il trattamento dell’osteoartrosi
PCT/IB2017/057685 WO2018104879A1 (en) 2016-12-06 2017-12-06 Composition for the treatment of osteoarthritis

Publications (1)

Publication Number Publication Date
MX2019006548A true MX2019006548A (es) 2019-10-07

Family

ID=58545064

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006548A MX2019006548A (es) 2016-12-06 2017-12-06 Composicion para el tratamiento de la osteoartritis.

Country Status (16)

Country Link
US (1) US11123354B2 (es)
EP (1) EP3551190A1 (es)
JP (1) JP7184792B2 (es)
KR (1) KR20190093616A (es)
CN (1) CN110167561A (es)
AR (1) AR110319A1 (es)
AU (1) AU2017371736A1 (es)
BR (1) BR112019011418A2 (es)
CA (1) CA3046116A1 (es)
CL (1) CL2019001507A1 (es)
EA (1) EA201991381A1 (es)
IL (1) IL267059A (es)
IT (1) IT201600123773A1 (es)
MX (1) MX2019006548A (es)
SG (1) SG10202105882PA (es)
WO (1) WO2018104879A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1187828B (it) * 1985-05-24 1987-12-23 Gentili Ist Spa Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi
DE4228552A1 (de) * 1992-08-27 1994-03-03 Boehringer Mannheim Gmbh Diphosphonsäuren und deren Salze enthaltende Arzneimittel
EP1136069A1 (en) * 2000-03-21 2001-09-26 SPA SOCIETA' PRODOTTI ANTIBIOTICI S.p.A. Pharmaceutical compositions containing clodronates for high local tolerance intramuscular administration
ITMI20052515A1 (it) * 2005-12-29 2007-06-30 Abiogen Pharma Spa Formulazione farmaceutica per il trattamento della osteoartrite
KR101102364B1 (ko) * 2009-09-18 2012-01-03 한림제약(주) 비스포스포네이트 유도체 및 고용량의 콜레칼시페롤을 포함하는 약학 조성물
ITMI20120393A1 (it) * 2012-03-14 2013-09-15 Tiberio Bruzzese Formulazioni acquose di bisfosfonati, vitamina d e alcol benzilico adatte all'uso intramuscolare o sottocutaneo
US9682099B2 (en) 2015-01-20 2017-06-20 DePuy Synthes Products, Inc. Compositions and methods for treating joints

Also Published As

Publication number Publication date
AR110319A1 (es) 2019-03-20
AU2017371736A1 (en) 2019-07-25
JP7184792B2 (ja) 2022-12-06
WO2018104879A1 (en) 2018-06-14
EA201991381A1 (ru) 2019-11-29
US20200061088A1 (en) 2020-02-27
EP3551190A1 (en) 2019-10-16
CA3046116A1 (en) 2018-06-14
US11123354B2 (en) 2021-09-21
CN110167561A (zh) 2019-08-23
IT201600123773A1 (it) 2018-06-06
BR112019011418A2 (pt) 2019-11-19
JP2020502265A (ja) 2020-01-23
SG10202105882PA (en) 2021-07-29
CL2019001507A1 (es) 2019-11-15
KR20190093616A (ko) 2019-08-09
IL267059A (en) 2019-08-29

Similar Documents

Publication Publication Date Title
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
JO3784B1 (ar) الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
PH12015502539A1 (en) Cenicriviroc compositions and methods of making and using the same
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
MY197785A (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
MX2019012884A (es) Terapia de combinacion.
AU2016354007A8 (en) Therapeutic compositions for treatment of human immunodeficiency virus
MX2019002265A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
PH12020550341A1 (en) Niraparib formulations
EA201792592A1 (ru) Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
RU2017134443A (ru) Способ лечения с применением традипитанта
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
EP4342473A3 (en) Compounds useful in hiv therapy
MX2018000084A (es) Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina.
PH12020500099A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
MX2019005104A (es) Composiciones de zinc-y-pga y métodos para tratar el cancer.
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
MY193963A (en) Composition for treating joint diseases and kit containing same
MX2016010892A (es) Agente para suprimir el progreso de o para mejorar la enfermedad renal cronica.
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.